Introducing Yourgene Health LightBench with Ranger technology

Yourgene health Lightbench with ranger technology | Medical Supply Company

MSC are proud to introduce the LightBench® with Ranger® Technology from Yourgene health to the Irish clinical and research laboratory market. Yourgene health is a global molecular diagnostics company that specializes in reproductive health and oncology. They provide innovative genetic testing solutions to healthcare professionals and patients worldwide. Their services include non-invasive prenatal testing (NIPT), preimplantation genetic screening (PGS), and various other genetic tests for reproductive health. Additionally, Yourgene Health offers genetic testing for cancer, including hereditary cancer risk assessment and liquid biopsy testing.

About the LightBench®

The LightBench®, powered by Ranger® Technology, is Yourgene’s research-grade size selection instrument that offers industry-leading scalability and precision for the DNA size selection process. This versatile automated gel electrophoresis instrument offers multiple types of functionality. The gel electrophoresis is automatically monitored in real time for applications that require size selection, or simply for fragment length analysis. The LightBench® is designed to work seamlessly with your Next-generation sequencing (NGS) workflow, specifically in the areas of NIPT and cancer diagnostics.

Since circulating cell-free DNA (cfDNA) fragments of both tumour and fetal origin are typically <150 bp in length, size selection using the LightBench® can enrich the fetal and tumour fraction in the individuals samples. It allows isolation and recovery of these specific fractions with consistently high intrinsic recovery yields, exceeding 70%, resulting in improved DNA quality and thus improved sequencing results.

Cancer screening

Liquid biopsy is a non-invasive method of sampling and analysing non-solid biological tissue using biomarkers circulating within bodily fluids, such as blood. A compelling application for this technology lies within oncology, in areas such as early routine diagnosis of cancer, as well as long-term monitoring of tumours and associated mutations. The technique works by examining circulating tumour DNA (ctDNA) within a patient’s blood sample. When tumour cells die, ctDNA is released into the blood, providing a molecular fingerprint which can be analysed using next-generation sequencing (NGS) technology. One of the challenges in making liquid biopsy a standard clinical tool lies in reducing the presence of both false positive/negative results.

Whilst sequencing has indeed become cheaper and cheaper, it has also to some extent become noisier. Sequencing ‘noise’ contributes towards diagnostic errors by making it more difficult to distinguish the tumour signal from the non-specific noise. The Yourgene health LightBench® with Ranger® Technology is designed to overcome this by enriching the sample through size selection, separating the ctDNA from the healthy cell DNA. The World Health Organization (WHO) estimates that the use of blood biopsies could have an impact in preventing 30-50% of cancers through earlier diagnosis and subsequent treatment.


NIPT is a method for assessing the risk of certain genetic conditions in a developing fetus during pregnancy without the need for invasive procedures like amniocentesis or chorionic villus sampling (CVS), which carry a small risk of miscarriage. Similar to the cancer screening, enrichment of the fetal fraction DNA from a maternal blood sample is achieved through size selection via automated gel electrophoresis using the yourgene health LightBench® with Ranger® Technology. This CE-marked in vitro diagnostic (IVD) tool allows for future sequencing in the diagnosis of a range of Trisomies, sex chromosome aneuploidies (SCAs) and relevant microdeletions.  

Advantages of using the LightBench® with Ranger® Technology

  • Reduction in the cost through the elimination of sequencing off target fragments
  • Reduction in time through the elimination of sequencing off target fragments
  • Improved patient outcomes due to the decrease in turnaround time
  • Lower pool concentrations of DNA needed (100pM) for subsequent NGS
  • Reduction in the need for both amniocentesis and tumour biopsies

View Yourgene Health LightBench® with Ranger® Technology informational video –

If you would like to receive any additional information in relation to the LightBench® with Ranger® Technology, please contact us below.

Get In Touch